Payment overview · 2025
General Payments
$2,894.25
125 reported records · 25 companies
Healthcare provider profile · identity verified
Daniel Franco, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAN BERNARDINO, CA · NPI 1568494151
Verified facts
What the public records show
CMS Open Payments records show Daniel Franco, M.D. received $2,894.25 in general payments during 2025 across 125 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $442.60 | 15.3% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $320.67 | 11.1% | 25 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $308.24 | 10.7% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $281.71 | 9.7% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $222.78 | 7.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $222.72 | 7.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $195.09 | 6.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.62 | 5.3% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $96.86 | 3.4% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.51 | 3.0% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $84.00 | 2.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.74 | 2.2% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $62.30 | 2.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.32 | 1.5% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $39.00 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.93 | 1.3% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $36.63 | 1.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.94 | 1.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $32.16 | 1.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $28.29 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.26 | 0.9% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.96 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.69 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.44 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.79 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,855.25 | 124 |
| Education | $39.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $308.24 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $281.71 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $224.48 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $222.56 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $204.37 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.67 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $172.31 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.71 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.44 | 6 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $123.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $97.13 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $96.86 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.72 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $84.00 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $82.52 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.93 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.38 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $65.72 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.74 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $62.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $47.02 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| FILSUVEZ Normalized: filsuvez |
Drug | Chiesi USA, Inc. | $39.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.04 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.43 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $33.43 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $33.43 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $24.44 | 2 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.54 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $5.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $4.54 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $4.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 112 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 263 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 296 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 216 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
263 | 78 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
296 | 99 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
296 | 99 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
171 | 38 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
112 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
216 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
262 | 53 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1860 | 611 |
| Metformin Hcl | Metformin Hcl | 1121 | 351 |
| Losartan Potassium | Losartan Potassium | 860 | 277 |
| Levothyroxine Sodium | Levothyroxine Sodium | 735 | 217 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 698 | 212 |
| Omeprazole | Omeprazole | 686 | 209 |
| Gabapentin | Gabapentin | 685 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 670 | 227 |
| Tamsulosin Hcl | Tamsulosin Hcl | 585 | 188 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 563 | 195 |
| Pantoprazole Sodium | Pantoprazole Sodium | 454 | 130 |
| Lisinopril | Lisinopril | 409 | 140 |
| Tramadol Hcl | Tramadol Hcl | 400 | 123 |
| Ibuprofen | Ibuprofen | 378 | 119 |
| Simvastatin | Simvastatin | 378 | 114 |
| Carvedilol | Carvedilol | 359 | 107 |
| Diclofenac Sodium | Diclofenac Sodium | 355 | 110 |
| Alendronate Sodium | Alendronate Sodium | 347 | 111 |
| Furosemide | Furosemide | 325 | 106 |
| Glipizide | Glipizide | 319 | 97 |
| Metformin Hcl Er | Metformin Hcl | 305 | 117 |
| Jardiance | Empagliflozin | 296 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 83 |
| Farxiga | Dapagliflozin Propanediol | 263 | 78 |
| Eliquis | Apixaban | 262 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 91 |
| Trazodone Hcl | Trazodone Hcl | 244 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 86 |
| Ozempic | Semaglutide | 216 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 205 | 69 |
| Naproxen | Naproxen | 203 | 72 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 196 | 52 |
| Meclizine Hcl | Meclizine Hcl | 181 | 74 |
| Finasteride | Finasteride | 179 | 63 |
| Quetiapine Fumarate | Quetiapine Fumarate | 179 | 38 |
| Meloxicam | Meloxicam | 176 | 75 |
| Trulicity | Dulaglutide | 171 | 38 |
| Azithromycin | Azithromycin | 170 | 145 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 169 | 76 |
| Memantine Hcl | Memantine Hcl | 162 | 48 |
| Baclofen | Baclofen | 160 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 60 |
| Hydrocortisone | Hydrocortisone | 155 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 47 |
| Famotidine | Famotidine | 146 | 46 |
| Enalapril Maleate | Enalapril Maleate | 140 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 50 |
| Mirtazapine | Mirtazapine | 135 | 34 |
| Benazepril Hcl | Benazepril Hcl | 128 | 38 |
| Lidocaine | Lidocaine | 123 | 49 |
| Potassium Chloride | Potassium Chloride | 122 | 33 |
| Clonidine Hcl | Clonidine Hcl | 118 | 30 |
| Ciclopirox | Ciclopirox | 116 | 42 |
| Januvia | Sitagliptin Phosphate | 116 | 36 |
| Entresto | Sacubitril/Valsartan | 112 | 27 |
| Ketoconazole | Ketoconazole | 110 | 51 |
| Nifedipine Er | Nifedipine | 109 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 107 | 39 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 106 | 43 |
| Ezetimibe | Ezetimibe | 101 | 34 |
| Linzess | Linaclotide | 101 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 100 | 44 |
| Lovastatin | Lovastatin | 97 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 94 | 82 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 24 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 90 | 28 |
| Glimepiride | Glimepiride | 89 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 25 |
| Dapagliflozin | Dapagliflozin Propanediol | 81 | 22 |
| Xarelto | Rivaroxaban | 80 | 19 |
| Fenofibrate | Fenofibrate | 78 | 34 |
| Humalog Kwikpen U-100 | Insulin Lispro | 77 | 30 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 25 |
| Celecoxib | Celecoxib | 73 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 55 |
| Cephalexin | Cephalexin | 65 | 50 |
| Allopurinol | Allopurinol | 64 | 18 |
| Montelukast Sodium | Montelukast Sodium | 64 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 63 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 50 |
| Lorazepam | Lorazepam | 62 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 15 |
| Atenolol | Atenolol | 57 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 20 |
| Levetiracetam | Levetiracetam | 57 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 57 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 45 |
| Nitroglycerin | Nitroglycerin | 56 | 27 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 54 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 53 | 26 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | 19 |
| Steglatro | Ertugliflozin Pidolate | 49 | 12 |
| Fluconazole | Fluconazole | 46 | 20 |
| Metronidazole | Metronidazole | 46 | 40 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Nystatin | Nystatin | 43 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 42 | suppressed |
| Myrbetriq | Mirabegron | 42 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Latanoprost | Latanoprost | 40 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 12 |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 13 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 35 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Kerendia | Finerenone | 33 | suppressed |
| Procto-Med Hc | Hydrocortisone | 31 | 13 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Clotrimazole | Clotrimazole | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 16 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 21 |
| Novofine 32 | Pen Needle, Diabetic | 25 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | 11 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 17 | 12 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 12 |
| Norpace Cr | Disopyramide Phosphate | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 11 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Apidra Solostar | Insulin Glulisine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Klor-Con 8 | Potassium Chloride | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,894.25 · 125 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, APLENZIN, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DUPIXENT, ENTRESTO, EVENITY, FARXIGA, FILSUVEZ, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QUTENZA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UPLIZNA, VAXELIS, VAXNEUVANCE, VERQUVO, VYNDAQEL, Veozah, WELLBUTRIN, WINREVAIR, Wegovy, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error